Danish Multinational Novo Nordisk A / S, one of the world’s leading manufacturers of insulin, one day raised the challenge of investigating how to prevent the threatening blindness of people with diabetes. To do this, they began to develop software in which a vectorial algorithm, based on a photograph of the ocular fund, made with a Retinograph, detects, in premature stages, indications of small lesions, which could in the future cause the loss of view.
In 2008, the crisis forced to stop the research and implementation, until Jens Thygesen, one of the ophthalmologists who participated in the creation of the software bought it and began using it in his hospital in Copenhagen.
In 2014, the analytical method was exported to the cloud and made accessible trough internet. Since its appearance in the market, RetinaLyze has quadrupled its profit. With a global expansion, it operates in Europe, the United States, China, Japan, India, Australia, among others. In China there are already 7000 public hospitals that use this method.
From Bolivia the expansion to Argentina, Brazil, Chile, Colombia, Uruguay and Peru begins, totalizing 7 countries for which we have the representation.